BiotechTube

Qizhi weitong granules(High） + Qizhi weitong granules(Low） + Placebo

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome

Conditions

Irritable Bowel Syndrome

Trial Timeline

Dec 1, 2021 → Dec 31, 2022

NCT ID
NCT05113888

About Qizhi weitong granules(High） + Qizhi weitong granules(Low） + Placebo

Qizhi weitong granules(High） + Qizhi weitong granules(Low） + Placebo is a phase 2 stage product being developed by China Resources Pharmaceutical Group for Irritable Bowel Syndrome. The current trial status is unknown. This product is registered under clinical trial identifier NCT05113888. Target conditions include Irritable Bowel Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05113888Phase 2UNKNOWN

Competing Products

20 competing products in Irritable Bowel Syndrome

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
52
YM060 + PlaceboAstellas PharmaPhase 3
77
Ramosetron + PlaceboAstellas PharmaApproved
85
Ramosetron + PlaceboAstellas PharmaApproved
85
YM060Astellas PharmaPhase 3
77
YM060 + placeboAstellas PharmaPhase 2
52
YM060Astellas PharmaPhase 3
77
linaclotide + PlaceboAstellas PharmaPhase 3
77
RamosetronAstellas PharmaPre-clinical
23
YM060Astellas PharmaPhase 2
52
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
52
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
52
duloxetineEli LillyApproved
85
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
77
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
77
Eluxadoline + PlaceboAbbViePhase 2
52
Placebo + LinaclotideAstraZenecaPhase 3
77
TegaserodNovartisPre-clinical
23
DNK333NovartisPhase 2
52
SMS995 + PlaceboNovartisPhase 1
33

Other Products from China Resources Pharmaceutical Group

Shenfu Zhusheye + 5% glucose injectionApproved
82
Jinfukang oral liquid + Platinum-based doublet chemotherapyApproved
82
Yuxuebi tablet + Placebo tabletApproved
82
Mifepristone tabletsApproved
82
Shenfu Injection + 5% Glucose InjectionApproved
82